
New director named at Celgene
pharmafile | March 14, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Celgene, moore
Biopharma firm Celgene has appointed Rob Moore as its new Inflammation and Immunology business unit director.
Moore has worked in the pharma industry for almost 20 years and began his career as a sales rep with Abbott, before working in a variety of primary care sales and marketing roles and progressing to the immunology division in 2006.
He spent seven years with the firm and worked across Western Europe and Canada, spending two years in Paris as Immunology commercial director, Dermatology. More recently he returned to the UK to take up the position of senior business unit manager, Rheumatology.
Sam Pearce, vice president and general manager at Celgene said: “We have an opportunity here to offer effective solutions to patients in need, and are confident that Rob has the knowledge and experience to help us deliver these.”
Related Content

NICE recommends Celgene’s REVLIMID for multiple myeloma
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …

NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …

NICE recommends Celgene’s Revlimid combo for follicular lymphoma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has …






